Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006).

Trial Profile

Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006).

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 03 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jan 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top